Vimarsana
Biggest News Aggregation in the World

Page 2 - Lilly Trulicity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lilly Trulicity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lilly Trulicity Today - Breaking & Trending Today

Europe to face shortage of Lilly's diabetes drug through September - Vimarsana News

Europe to face shortage of Lilly's diabetes drug through September

Like rival Novo Nordisk, Eli Lilly has also been struggling to meet high demand for its diabetes drugs including Trulicity, which treats type 2 diabetes in people older than 10. Novo's diabetes drug Ozempic was in short supply for months in the U.S., partly driven by prescriptions to non-diabetic patients seeking to lose weight.

Source: aol.com
Why suicide risks may spoil the debut of the latest weight loss drugs - Vimarsana News

Why suicide risks may spoil the debut of the latest weight loss drugs

Investors could be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week.

Source: cnbc.com
Biopharma Facing Two Major Crises - A Huge Patent Cliff And Price Controls - Vimarsana News

Biopharma Facing Two Major Crises - A Huge Patent Cliff And Price Controls

Out of necessity, the industry will have to make significant cuts to its R&D operations. Research sites will be cut back or eliminated, therapeutic areas will be dropped and jobs will be lost.

Source: forbes.com
Obesity Drug Stocks: Time to Buy Makers of Ozempic, Mounjaro, Others? - Vimarsana News

Obesity Drug Stocks: Time to Buy Makers of Ozempic, Mounjaro, Others?

Weight-loss drugs could be a $60 billion market in 10 years. These companies stand to benefit.

Blackstone using AI to control employees' diabetes and cut spending on expensive drugs - Vimarsana News

Blackstone using AI to control employees' diabetes and cut spending on expensive drugs

The private equity giant is testing a program from startup Twin Health with workers across 14 of its portfolio companies. The app is designed to help diabetics rely less on expensive drugs to lose weight and control their blood sugar